CCR5 receptor expression is down-regulated in HIV type 2 infection: Implication for viral control and protection

AIDS Research and Human Retroviruses

Volumn 20, Issue 6, 2004, Pages 630-635

  Shea, A ^a   Dieng Sarr, A ^b   Jones, N ^a   Penning, L ^a   Eisen, G ^b   Gueye Ndiaye, A ^c   Mboup, S ^c   Kanki, P ^b   Cao, H ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; BIOCHEMICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; HLA DR ANTIGEN;

ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFECTION CONTROL; INFECTION PREVENTION; PRIORITY JOURNAL; PROSTITUTION; PROTEIN EXPRESSION; SEROLOGY; T LYMPHOCYTE; UPREGULATION; VIRUS LOAD;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES, CC; CYTOKINES; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; HIV INFECTIONS; HIV-2; HLA-DR ANTIGENS; HUMANS; RECEPTORS, CCR5; SENEGAL; VIRAL LOAD;

EID: 3042689428     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/0889222041217383     Document Type: Article

References (45)

1. Kanki PJ, Travers KU, MBoup S, Hsieh CC, Marlink RG, Gueye-NDiaye A, Siby T, Thior I, Hernandez-Avila M, Sankale JL, Ndoye I, and Essex M: Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994;343:943-946.
2. Kanki P, Sankale J-L, and Mboup S: Biology of human immunodeficiency virus type 2 (HIV2). In: AIDS in Africa, 2nd ed. (Essex M, MBoup S, Kanki P, Marlink R, and Tlou SD, eds.). Kluwer Academic/Plenum Publisher, New York, 2002, pp. 75-103.
3. Essex M and Kanki P: Human immunodeficiency virus type 2 (HIV-2). In: Textbook of AIDS Medicine (Broders S, Merigan T, and Bologenesi D, eds.). Williams & Wilkins, Baltimore, 1994, pp. 873-886.
4. Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R, and Whittle H: Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1998;1:457-468.
5. Popper SJ, Dieng-Sarr A, Gueye-Ndiaye A, MBoup S, Essex M, and Kanki P: Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: Low virus production in vivo. J Virol 2000;74:1554-1557.
6. Bjorling E, Scarlatti G, von Gegerfelt A, Albert J, Biberfeld G, Chiodi F, Norrby E, and Fenyo EM: Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993;193:528-530.
7. Dieng-Sarr A, Lu Y, Sankale J-L, Eisen G, Popper SJ, Mboup S, Kanki P, and Cao H: Robust HIV-2 cellular immune response measured by a modified anthrax toxin-based elispot assay. AIDS Res Hum Retroviruses 2001;17:1257-1264.
8. Travers K, MBoup S, Marlink R, Gueye-NDiaye A, Siby T, Thior I, Traore I, Dieng-Sarr A, Sankale J, Mullins C, NDoye I, Hsieh C, Essex M, and Kanki P: Natural protection against HIV-1 infection provided by HIV-1. Science 1995;268:1612-1615.
9. Travers K, Eisen G, Marlink RG, Essex M, Hsieh CC, Mboup S, and Kanki P: Protection from HIV-1 infection by HIV-2. AIDS 1996;12:224-225.
10. Norrgren H, Andersson S, Biague AJ, da Silva ZJ, Dias F, Naucler A, and Biberfeld G: Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, West Africa: No protection of HIV-2 against HIV-1 infection: AIDS 1999;13:701-707.
11. Kokkotou E, Sankale JL, Guye-Ndiaye A, Scwartz D, Essex ME, MBoup S, and Kanki P: In vitro correlates of HIV-2-mediated HIV-1 infection. Proc Natl Acad Sci USA 2000;97:6797-6802.
12. Bertoletti A, Cham F, McAdam S, Rostron T, Rowland-Jones S, Sabally S, Corrah T, Ariyoshi K, and Whittle H: Cytotoxic T cells from human immunodeficiency virus type-2 infected patients frequently cross-react with different human immunodeficiency virus type 1 clades. J Virol 1998;72:2439-2448.
13. Deng H, Unutmaz D, KewalRamani VN, and Littman DR: Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997;388:296-300.
14. Azevedo-Pereira JM, Santos-Costa Q, Mansinho K, and Moniz-Pereira J: Identification and characterization of HIV-2 strains obtained from asymptomatic patients that do not use CCR5 or CXCR4 coreceptors. Virology 2003;313:136-146.
15. Morner A, Bjorndal A, Leandersson AC, Albert J, Bjorling E, and Jansson M: CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates. AIDS Res Hum Retroviruses 2002;18:193-200.
16. Morner A, Thomas JA, Bjorling E, Munson PJ, Lucas SB, and McKnight A: Productive HIV-2 infection in the brain is restricted to macrophages/microglia. AIDS 2003;17:1451-1455.
17. Blanpain C, Libert F, Vassart G, and Parmentier M: CCR5 and HIV infection. Receptors Channels 2002;8:19-31.
18. Weiss RA: HIV receptors and cellular tropism. IUBMB Life 2002;53:201-205.
19. Schramm B, Penn ML, Palacios EH, Grant RM, Kirchhoff F, and Goldsmith MA: Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J Virol 2000;74:9594-9600.
20. Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, Thorstensson R, Fenyo EM, and Bjorling E: Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999;73:2343-2349.
21. Huang Y, Paxton WA, Wolinski SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, and Koup RA: The role of a mutant CCCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243.
22. Bratt G, Sandstrom E, Albert J, Samson M, and Wahren B: The influence of MT-2 tropism on the prognostic implications of the delta32 deletion in the CCCR5-gene. AIDS 1997;11:1415-1419.
23. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski I, Newman W, Koup RA, and Mackay CR: CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997;185:1681-1691.
24. Kanki P, Mboup S, Marlink R, Travers K, Ksieh C, Gueye A, Boye C, Sankale J, Donnelly C, Leisenring W, Siby T, Thior I, Dia M, Gueye E, N'Doye I, and Essex M: Prevalence and risk determinants of human immunodeficiency virus type 2 (HIV-2) and human immunodeficiency virus type 1 (HIV-1) in West African female prostitutes. Am J Epidemiol 1992;136:895-907.
25. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh C, Dia M, Gueye E, Hellinger J, Gueye-Ndiaye A, Sankale J, Ndoye I, MBoup S, and Essex M: Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265:1587-1590.
26. Wong JT and Colvin RB: Bi-specific monoclonal antibodies: Selective binding and complement fixation to cells that express two different surface antigens. J Immunol 1987;139:1369-1374.
27. Kalams S, Johnson RP, Dynan MJ, Hartman KE, Harrer T, Harrer E, Trocha AK, Blattner WA, Buchbinder SP, and Walker BD: T cell receptor usage and fine specificity of human immunodeficiency virus-1-specific cytotoxic T lymphocyte clones: Analysis of quasispecies recognition reveals a dominant response directed against a minor in vivo variant. J Exp Med 1996;183:1669-1679.
28. Johnson RP, Trocha A, Yang L, Mazzara GP, Panicali DL, Buchanan TM, and Walker BD: HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol 1991;147:1512-1521.
29. Romano JW, Tetali S, Lee EM, Shurtliff RN, Wang XP, Pahwa S, Kaphlan MHN, and Ginocchio CC: Genotyping of the CCR5 chemokine receptor by isothermal NASBA amplification and differential probe hybridization. Clin Diagn Lab Immunol 1999;6:959-965.
30. Boom R, Sol CJA, Salimans M, Jansen CL, Wertheim-van Dillen PME, and van der Noordaa J: Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
31. Clerici M, Butto S, Lukwiya M, Saresella M, Delich S, Trabattoni D, Pastori C, Piconi C, Fracasso C, Fabiani M, Ferrante P, Rizzardini G, and Lopalco L: Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS 2000;14:2083-2092.
32. Ostrowski MA, Justement SJ, Cantazaro A, Hallahan CA, HEhler LA, Mizell SB, Kumar PN, Mican JA, Chun T-W, and Fauci A: Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 1998;161:3195-3201.
33. de Roda Husman A-M, Blaak H, Brouwer M, and Schuitemaker H: CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J Immunol 1999;163:4597-4603.
34. Oishi K, Hayano M, Yoshimine H, Tugume SG Kebba A, Mugerwa R, Mugyenyi P, Kumatori A, Matsushima K, and Nagatake T: Expression of chemokine receptors on CD4+ T cells in peripheral blood from HIV-infected individuals in Uganda. J Interferon Cytokine Res 2000;20:597-602.
35. Reynes J, Portales P, Segondy M, Baillat V, Andre P, Avinens O, Picot MC, Clot J, Eliaou JF, and Corbeau P: CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS 2001;15:1627-1634.
36. Reynes J, Portales P, Segondy M, Baillat V, Andre P, Reant B, Avinens O, Couderc G, Benkirane M, Clot J, Eliaou JF, and Corbeau P: CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis 2000;181:927-932.
37. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, and Victorino RMM: CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002;169:3400-3406.
38. Samson M, Libert F, Doranz bJ, Rucker J, Liesnard C, Farber C-M, Saragosti C, Lapoumeroulie C, Cognaux J, Forceille C, Muylderman G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, and Parmentier M: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-725.
39. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, and Stuhlmann H: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:382.
40. Dean M, Carrington M, Winkler C, Huttley G, Smith M, Allikmets R, Goedert J, Buchbinder S, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, and O'Brien S: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE study. Science 1996;273:1856-1862.
41. Berger EA, Murphy PM, and Farber JM: Chemokine receptors as HIV-1 coreceptors: Role in viral entry, tropism and disease. Annu Rev Immunol 1999;17:657-700.
42. Ramaley PA, French N, Kaleebu P, Gilks C, Whitworth J, and Hill AVS: HIV in Africa: Chemokine-receptor genes and AIDS risk. Nature 2002;417:140.
43. Kokkotou E, Philippon V, Gueye-Ndiaye A, MBoup S, Wang W-K, Essex M, and Kanki P: Role of the CCR5Δ32 allele in resistance to HIV-1 infection in West Africa. J Hum Virol 1998;1:469-474.
44. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
45. Wagner L, Yang OO, Garcia-Zepeda EA, Ge Y, Kalams S, Walker BD, Pasternack MS, and Luster AD: Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 1998;391:908-911.